Cristian Vilos

Prof. Dr. Cristian Vilos


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2014 in Journal of Controlled Release
Verified
Journal Article
Closed access
BYBasit Yameen
Basit Yameen
WCWon Il Choi
Won Il Choi
CVCristian Vilos
Cristian Vilos
ASArchana Swami
Archana Swami
JSJinjun Shi
Jinjun Shi
OFOmid C. Farokhzad
Omid C. Farokhzad

28 April 2016 in ACS Nano
Verified
Journal Article
Closed access
NKNazila Kamaly
Nazila Kamaly
GFGabrielle Fredman
Gabrielle Fredman
JFJhalique Jane R. Fojas
Jhalique Jane R. Fojas
MSManikandan Subramanian
Manikandan Subramanian
WCWon Ii Choi
Won Ii Choi
OFOmid C. Farokhzad
Omid C. Farokhzad

22 June 2011 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
JSJinjun Shi
Jinjun Shi
ZXZeyu Xiao
Zeyu Xiao
AVAlexander R. Votruba
Alexander R. Votruba
CVCristian Vilos
Cristian Vilos
OFOmid C. Farokhzad
Omid C. Farokhzad

16 August 2016 in Nanomedicine
Verified
Journal Article
Closed access
BCBruno A Cisterna
Bruno A Cisterna
NKNazila Kamaly
Nazila Kamaly
WCWon Il Choi
Won Il Choi
ATAli Tavakkoli
Ali Tavakkoli
OFOmid C Farokhzad
Omid C Farokhzad
CVCristian Vilos
Cristian Vilos
Colorectal cancer (CRC) is highly prevalent worldwide, and despite notable progress in treatment still leads to significant morbidity and mortality. The use of nanoparticles as a drug delivery system has become one of the most promising strategies for cancer therapy. Targeted nanoparticles could take advantage of differentially expressed molecules on the surface of tumor cells, providing effective release of cytotoxic drugs. Several efforts have recently reported the use of diverse molecules as ligands on the surface of nanoparticles to interact with the tumor cells, enabling the effective delivery of antitumor agents. Here, we present recent advances in targeted nanoparticles against CRC and discuss the promising use of ligands and cellular targets in potential strategies for the treatment of CRCs.

3 January 2017 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
JPJuan P. Peñaloza
Juan P. Peñaloza
VMValeria Márquez-Miranda
Valeria Márquez-Miranda
MCMauricio Cabaña-Brunod
Mauricio Cabaña-Brunod
RRRodrigo Reyes-Ramírez
Rodrigo Reyes-Ramírez
FLFelipe Marchant Llancalahuen
Felipe Marchant Llancalahuen
Carolina OteroCarolina Otero
Carolina Otero
Nanotechnology is a science that involves imaging, measurement, modeling and a manipulation of matter at the nanometric scale. One application of this technology is drug delivery systems based on nanoparticles obtained from natural or synthetic sources. An example of these systems is synthetized from poly(3-hydroxybutyrate-co-3-hydroxyvalerate), which is a biodegradable, biocompatible and a low production cost polymer. The aim of this work was to investigate the uptake mechanism of PHBV nanoparticles in two different epithelial cell lines (HeLa and SKOV-3). As a first step, we characterized size, shape and surface charge of nanoparticles using dynamic light scattering and transmission electron microscopy. Intracellular incorporation was evaluated through flow cytometry and fluorescence microscopy using intracellular markers. We concluded that cellular uptake mechanism is carried out in a time, concentration and energy dependent way. Our results showed that nanoparticle uptake displays a cell-specific pattern, since we have observed different colocalization in two different cell lines. In HeLa (Cervical cancer cells) this process may occur via classical endocytosis pathway and some internalization via caveolin-dependent was also observed, whereas in SKOV-3 (Ovarian cancer cells) these patterns were not observed. Rearrangement of actin filaments showed differential nanoparticle internalization patterns for HeLa and SKOV-3. Additionally, final fate of nanoparticles was also determined, showing that in both cell lines, nanoparticles ended up in lysosomes but at different times, where they are finally degraded, thereby releasing their contents. Our results, provide novel insight about PHBV nanoparticles internalization suggesting that for develop a proper drug delivery system is critical understand the uptake mechanism.

26 February 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
CCCisterna Cisterna
Cisterna Cisterna
AVAníbal A. Vargas
Aníbal A. Vargas
CPCarlos Puebla
Carlos Puebla
PFPaola Fernández
Paola Fernández
RERosalba Escamilla
Rosalba Escamilla
Juan Carlos SaezJuan Carlos Saez
Juan Carlos Saez
Denervation of skeletal muscles induces severe muscle atrophy, which is preceded by cellular alterations such as increased plasma membrane permeability, reduced resting membrane potential and accelerated protein catabolism. The factors that induce these changes remain unknown. Conversely, functional recovery following denervation depends on successful reinnervation. Here, we show that activation of nicotinic acetylcholine receptors (nAChRs) by quantal release of acetylcholine (ACh) from motoneurons is sufficient to prevent changes induced by denervation. Using in vitro assays, ACh and non-hydrolysable ACh analogs repressed the expression of connexin43 and connexin45 hemichannels, which promote muscle atrophy. In co-culture studies, connexin43/45 hemichannel knockout or knockdown increased innervation of muscle fibers by dorsal root ganglion neurons. Our results show that ACh released by motoneurons exerts a hitherto unknown function independent of myofiber contraction. nAChRs and connexin hemichannels are potential molecular targets for therapeutic intervention in a variety of pathological conditions with reduced synaptic neuromuscular transmission.